FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296533008> ?p ?o ?g. }

• W4296533008 endingPage "S230" @default.
• W4296533008 startingPage "S230" @default.
• W4296533008 abstract "Gilteritinib, an oral FLT3 inhibitor, demonstrated antileukemic responses in patients with FLT3mut+ relapsed/refractory AML.Present final data from a phase 1 study of once-daily gilteritinib plus intensive chemotherapy in newly diagnosed (ND) AML.This 4-part, open-label study (NCT02236013) assessed gilteritinib dose/schedule and effects of alternative anthracycline treatment.Gilteritinib plus 7+3 induction with idarubicin or daunorubicin, plus ≤3 cycles of high-dose cytarabine and gilteritinib consolidation, and 2 years of single-agent gilteritinib maintenance treatment post consolidation or transplant.Adults with ND AML; FLT3 mutation not required for enrollment (known core binding factor fusions excluded).Safety, tolerability, PK, antileukemic effects.Eighty patients were allocated to gilteritinib (safety analysis set, n=78 [age 23-77 y]; FLT3mut+, n=44 [FLT3-ITD, n=33]). Median follow-up was 37.7 months. On-study HSCT was performed in 27/80 (33.8%) patients (FLT3mut+, 26/44 [59.1%]). Dose-limiting toxicities occurred in 15/78 (19.2%) patients (200-mg/d cohort: neutropenia, n=1; neutropenic colitis, n=1). Maximum tolerated dose was 120 mg/d. Across the study, AEs led to gilteritinib discontinuation in 24.4% of patients. At end-of-treatment, composite complete remission (CRc: complete remission [CR] + CR with incomplete hematologic recovery [CRi] + CR with incomplete platelet recovery [CRp]), CR, CRi, and CRp rates were 79.7%, 54.4%, 21.5%, and 3.8%, respectively, in the overall population and 90.9%, 70.5%, 13.6%, and 6.8% among FLT3mut+ patients. In the overall (n=79) and FLT3mut+ populations (n=44), 60-day mortality rates were 1.3% and 0%, respectively, and median (95% CI) disease-free survival was 15.1 (9.5, 31.9) and 15.1 (4.9, 31.9) months. In the overall (n=69) and FLT3mut+ populations (n=41) receiving ≥80 mg/d, median (95% CI) OS was 38.6 (21.7, NE) and 45.9 (30.8, NE) months, respectively, and the estimated 3-year OS rate was 56.0% and 60.1%. Anthracycline choice did not substantially impact CRc rate or toxicity. In patients who achieved CRc with gilteritinib ≥120 mg/d, mutational clearance of FLT3-ITD (summed FLT3 ITD:wildtype signal ratio ≤10-4) after consolidation was 84.6% (11/13).Gilteritinib plus induction and consolidation chemotherapy was well tolerated and resulted in CR, FLT3-ITD clearance, and long-term survival in patients with ND FLT3mut+ AML, supporting ongoing randomized trials testing this approach against current standards." @default.
• W4296533008 created "2022-09-21" @default.
• W4296533008 creator A5013926915 @default.
• W4296533008 creator A5015755664 @default.
• W4296533008 creator A5019963455 @default.
• W4296533008 creator A5025780450 @default.
• W4296533008 creator A5025872351 @default.
• W4296533008 creator A5028012131 @default.
• W4296533008 creator A5030404045 @default.
• W4296533008 creator A5035236340 @default.
• W4296533008 creator A5037299848 @default.
• W4296533008 creator A5037460404 @default.
• W4296533008 creator A5045709974 @default.
• W4296533008 creator A5055141093 @default.
• W4296533008 creator A5055703943 @default.
• W4296533008 creator A5063166319 @default.
• W4296533008 creator A5077421212 @default.
• W4296533008 creator A5089694123 @default.
• W4296533008 date "2022-10-01" @default.
• W4296533008 modified "2023-10-16" @default.
• W4296533008 title "AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results" @default.
• W4296533008 doi "https://doi.org/10.1016/s2152-2650(22)01255-1" @default.
• W4296533008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36163799" @default.
• W4296533008 hasPublicationYear "2022" @default.
• W4296533008 type Work @default.
• W4296533008 citedByCount "1" @default.
• W4296533008 countsByYear W42965330082023 @default.
• W4296533008 crossrefType "journal-article" @default.
• W4296533008 hasAuthorship W4296533008A5013926915 @default.
• W4296533008 hasAuthorship W4296533008A5015755664 @default.
• W4296533008 hasAuthorship W4296533008A5019963455 @default.
• W4296533008 hasAuthorship W4296533008A5025780450 @default.
• W4296533008 hasAuthorship W4296533008A5025872351 @default.
• W4296533008 hasAuthorship W4296533008A5028012131 @default.
• W4296533008 hasAuthorship W4296533008A5030404045 @default.
• W4296533008 hasAuthorship W4296533008A5035236340 @default.
• W4296533008 hasAuthorship W4296533008A5037299848 @default.
• W4296533008 hasAuthorship W4296533008A5037460404 @default.
• W4296533008 hasAuthorship W4296533008A5045709974 @default.
• W4296533008 hasAuthorship W4296533008A5055141093 @default.
• W4296533008 hasAuthorship W4296533008A5055703943 @default.
• W4296533008 hasAuthorship W4296533008A5063166319 @default.
• W4296533008 hasAuthorship W4296533008A5077421212 @default.
• W4296533008 hasAuthorship W4296533008A5089694123 @default.
• W4296533008 hasConcept C126322002 @default.
• W4296533008 hasConcept C141071460 @default.
• W4296533008 hasConcept C197934379 @default.
• W4296533008 hasConcept C2776694085 @default.
• W4296533008 hasConcept C2778375690 @default.
• W4296533008 hasConcept C71924100 @default.
• W4296533008 hasConcept C90924648 @default.
• W4296533008 hasConceptScore W4296533008C126322002 @default.
• W4296533008 hasConceptScore W4296533008C141071460 @default.
• W4296533008 hasConceptScore W4296533008C197934379 @default.
• W4296533008 hasConceptScore W4296533008C2776694085 @default.
• W4296533008 hasConceptScore W4296533008C2778375690 @default.
• W4296533008 hasConceptScore W4296533008C71924100 @default.
• W4296533008 hasConceptScore W4296533008C90924648 @default.
• W4296533008 hasLocation W42965330081 @default.
• W4296533008 hasLocation W42965330082 @default.
• W4296533008 hasOpenAccess W4296533008 @default.
• W4296533008 hasPrimaryLocation W42965330081 @default.
• W4296533008 hasRelatedWork W2002120878 @default.
• W4296533008 hasRelatedWork W2003938723 @default.
• W4296533008 hasRelatedWork W2047967234 @default.
• W4296533008 hasRelatedWork W2118496982 @default.
• W4296533008 hasRelatedWork W2364998975 @default.
• W4296533008 hasRelatedWork W2439875401 @default.
• W4296533008 hasRelatedWork W4238867864 @default.
• W4296533008 hasRelatedWork W4245874507 @default.
• W4296533008 hasRelatedWork W2519357708 @default.
• W4296533008 hasRelatedWork W2525756941 @default.
• W4296533008 hasVolume "22" @default.
• W4296533008 isParatext "false" @default.
• W4296533008 isRetracted "false" @default.
• W4296533008 workType "article" @default.